OBJECTIVE: The objective of this study is to determine the epidemiological effectiveness of a first-line antiretroviral regimen with HIV protease inhibitor for preventing recurrent malaria in children under the range of HIV prevalence levels and malaria transmission intensities encountered in sub-Saharan Africa. DESIGN: A dynamic model of malaria transmission was developed using clinical data on the protease inhibitor extended posttreatment prophylactic effect of the antimalarial treatment, artemether-lumefantrine, in addition to parameter estimates from the literature. METHODS: To evaluate the benefits of HIV protease inhibitors on the health burden of recurrent malaria among children, we constructed a dynamic model of malaria transmission to both HIV-positive and HIV-negative children, parameterized by data from a recent clinical trial. The model was then evaluated under varying malaria transmission and HIV prevalence settings to determine the health benefits of HIV protease inhibitors in the context of artemether-lumefantrine treatment of malaria in children. RESULTS: Comparing scenarios of low, intermediate and high newborn HIV prevalence, in a range of malaria transmission settings, our dynamic model predicts that artemether-lumefantrine with HIV protease inhibitor based regimens prevents 0.03-0.10, 5.2-13.0 and 25.5-65.8 annual incidences of malaria per 1000 children, respectively. In addition, HIV protease inhibitors save 0.002-0.006, 0.22-0.8, 1.04-4.3 disability-adjusted life-years per 1000 children annually. Considering only HIV-infected children, HIV protease inhibitors avert between 278 and 1043 annual incidences of malaria per 1000 children. CONCLUSION: The use of HIV protease inhibitor based regimens as first-line antiretroviral therapy for HIV is an effective measure for reducing recurrent malaria among HIV-infected children in areas where HIV and malaria are coendemic, and artemether-lumefantrine is a first-line antimalarial.
OBJECTIVE: The objective of this study is to determine the epidemiological effectiveness of a first-line antiretroviral regimen with HIV protease inhibitor for preventing recurrent malaria in children under the range of HIV prevalence levels and malaria transmission intensities encountered in sub-Saharan Africa. DESIGN: A dynamic model of malaria transmission was developed using clinical data on the protease inhibitor extended posttreatment prophylactic effect of the antimalarial treatment, artemether-lumefantrine, in addition to parameter estimates from the literature. METHODS: To evaluate the benefits of HIV protease inhibitors on the health burden of recurrent malaria among children, we constructed a dynamic model of malaria transmission to both HIV-positive and HIV-negative children, parameterized by data from a recent clinical trial. The model was then evaluated under varying malaria transmission and HIV prevalence settings to determine the health benefits of HIV protease inhibitors in the context of artemether-lumefantrine treatment of malaria in children. RESULTS: Comparing scenarios of low, intermediate and high newborn HIV prevalence, in a range of malaria transmission settings, our dynamic model predicts that artemether-lumefantrine with HIV protease inhibitor based regimens prevents 0.03-0.10, 5.2-13.0 and 25.5-65.8 annual incidences of malaria per 1000 children, respectively. In addition, HIV protease inhibitors save 0.002-0.006, 0.22-0.8, 1.04-4.3 disability-adjusted life-years per 1000 children annually. Considering only HIV-infectedchildren, HIV protease inhibitors avert between 278 and 1043 annual incidences of malaria per 1000 children. CONCLUSION: The use of HIV protease inhibitor based regimens as first-line antiretroviral therapy for HIV is an effective measure for reducing recurrent malaria among HIV-infectedchildren in areas where HIV and malaria are coendemic, and artemether-lumefantrine is a first-line antimalarial.
Authors: Sunil Parikh; Jiri Gut; Eva Istvan; Daniel E Goldberg; Diane V Havlir; Philip J Rosenthal Journal: Antimicrob Agents Chemother Date: 2005-07 Impact factor: 5.191
Authors: Charlotte V Hobbs; Takeshi Q Tanaka; Olga Muratova; Jillian Van Vliet; William Borkowsky; Kim C Williamson; Patrick E Duffy Journal: J Infect Dis Date: 2013-03-28 Impact factor: 5.226
Authors: U Lek-Uthai; R Suwanarusk; R Ruengweerayut; T S Skinner-Adams; F Nosten; D L Gardiner; P Boonma; K A Piera; K T Andrews; B Machunter; J S McCarthy; N M Anstey; R N Price; B Russell Journal: Antimicrob Agents Chemother Date: 2008-04-28 Impact factor: 5.191
Authors: Louise Kuhn; Gillian Hunt; Karl-Günter Technau; Ashraf Coovadia; Johanna Ledwaba; Sam Pickerill; Martina Penazzato; Silvia Bertagnolio; Claude A Mellins; Vivian Black; Lynn Morris; Elaine J Abrams Journal: AIDS Date: 2014-07-17 Impact factor: 4.177
Authors: Eline L Korenromp; Brian G Williams; Sake J de Vlas; Eleanor Gouws; Charles F Gilks; Peter D Ghys; Bernard L Nahlen Journal: Emerg Infect Dis Date: 2005-09 Impact factor: 6.883
Authors: Taylor G Sandison; Jaco Homsy; Emmanuel Arinaitwe; Humphrey Wanzira; Abel Kakuru; Victor Bigira; Julius Kalamya; Neil Vora; James Kublin; Moses R Kamya; Grant Dorsey; Jordan W Tappero Journal: BMJ Date: 2011-03-31
Authors: Charlotte V Hobbs; Erin E Gabriel; Portia Kamthunzi; Gerald Tegha; Jean Tauzie; Elizabeth Petzold; Linda Barlow-Mosha; Benjamin H Chi; Yonghua Li; Tiina Ilmet; Brian Kirmse; Jillian Neal; Sunil Parikh; Nagamah Deygoo; Patrick Jean Philippe; Lynne Mofenson; William Prescott; Jingyang Chen; Philippa Musoke; Paul Palumbo; Patrick E Duffy; William Borkowsky Journal: PLoS One Date: 2016-12-09 Impact factor: 3.240
Authors: Ronnie P Kasirye; Heiner Grosskurth; Paula Munderi; Jonathan Levin; Zacchaeus Anywaine; Andrew Nunn; Anatoli Kamali; Kathy Baisley Journal: AIDS Date: 2017-02-20 Impact factor: 4.177